Table 1.
Baseline Patient Characteristics
| Characteristics | IP therapy | Without IP therapy |
| (n = 230) | (n = 179) | |
| Age | ||
| <41 | 33 | 27 |
| 41–60 | 172 | 138 |
| >60 | 14 | 25 |
| FIGO stage | ||
| IIIa | 19 | 8 |
| IIIb | 22 | 6 |
| IIIc | 148 | 128 |
| IV | 41 | 37 |
| Residual disease | ||
| ≤ 1 cm | 123 | 68 |
| > 1 cm | 107 | 111 |
| Grade | ||
| 1 | 8 | 4 |
| 2 | 100 | 67 |
| 3 | 122 | 107 |
| Not available | 0 | 1 |
| Histology | ||
| Serous | 116 | 88 |
| Mucinous | 13 | 18 |
| Endometrioid | 25 | 16 |
| Unspecified adenocarcinoma | 44 | 37 |
| Mixed | 7 | 7 |
| Clear cell | 18 | 7 |
| Others | 7 | 6 |
Abbreviation: IP, intraperitoneal; FIGO, International Federation of Gynecology and Obstetrics.